Post by TechNews180

German Biotech Tubulis GmbH Secures €308M Series C Key Points 👇 ❶ German biotech Tubulis raised €308 million in Europe's largest-ever biotech Series C, led by Venrock Healthcare Capital Partners. ❷ The funding will expand clinical trials for TUB-040 in ovarian and lung cancer into earlier treatment stages. ❸ Venrock, Wellington Management, Ascenta Capital, and existing investors including EQT Life Sciences and Frazier backed the round. “This landmark financing round reflects the deep conviction these global healthcare investors have in Tubulis and the disruptive potential of our ADC platforms. With TUB-040 progressing in the clinic and first data to be shared in a late-breaking oral presentation at ESMO, we are ready to expand into earlier treatment lines, while continuing to innovate across our pipeline and technology platforms. The new funding empowers us to execute on our vision of creating truly differentiated antibody-drug conjugates that are tailored to the biology of solid tumors and can deliver superior therapeutic value to patients.” - Dr. Dominik Schumacher, CEO and Co-founder of Tubulis. #Biotech #CancerResearch #VentureCapital #DrugDevelopment #HealthcareInnovation https://lnkd.in/ezWhuJGn